Aethlon Medical soars 63% as FDA amends Hemopurifier IDE for COVID-19 treatment

 

• The first patient has been treated in Aethlon Medical's (NASDAQ:AEMD) first-in-human Early Feasibility Study (EFS) evaluating the Hemopurifier in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
• The EFS study includes 10 to 12 subjects. The primary endpoint is safety of the Hemopurifier in a clinical setting. Secondary endpoints include efficacy based on response rates, progression-free and overall survival, and changes in exosome concentration.
• In cancer, exosomes have been shown to participate in the development and advancement of disease.
• Additionally, the FDA has also approved an amendment to Aethlon's open Investigational Device Exemption (IDE) for the Hemopurifier in life threatening viral infections, to allow for the treatment of patients with SARS-CoV-2/COVID-19 infection.
• This will allow for up to 40 of these patients to be treated under a New Feasibility Study protocol.
• https://seekingalpha.com/news/3644849-aethlon-medical-aemd-stock-rockets-63-fda-amends-hemopurifier-ide-for-covidminus-19-treatment